Read about the latest developments in the world of lung cancer. You'll find articles from the last 24 months.

April 2024

:
FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lu…
(US Food and Drug Administration)
:
Colorless, odorless gas likely linked to alarming rise in non-smoking lung canc…
(American Association for the Advancement of Science)
:
Optimizing Biomarker Testing in Early-Stage Disease for Patients With NSCLC
(Targeted Oncology)
:
Neoadjuvant Use of ICB in NSCLC Gains Favor
(Targeted Oncology)

March 2024

:
FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell…
(US Food and Drug Administration)

February 2024

:
FDA Oks Osimertinib Plus Chemo in EGFR-Mutant Lung Cancer
(Targeted Oncology)
:
FDA Approves Tepotinib for Metastatic NSCLC Harboring MET Exon 14 Skipping Alte…
(OncLive)

November 2023

:
FDA approves repotrectinib for ROS1-positive non-small cell lung cancer
(US Food and Drug Administration)

October 2023

:
FDA approves neoadjuvant/ adjuvant pembrolizumab for resectable non-small cell …
(US Food and Drug Administration)
:
FDA approves encorafenib with binimetinib for metastatic non-small cell lung ca…
(US Food and Drug Administration)

April 2023

:
AACR: Lung cancer outcomes significantly improved with immunotherapy-based trea…
(AAAS)

February 2023

:
First-Line Combination Immunotherapy plus Chemotherapy in mNSCLC
(Targeted Oncology)
:
Toripalimab Plus Platinum Doublet Chemotherapy Prolongs EFS in Resectable NSCLC
(Targeted Oncology)

January 2023

:
FDA Approves Adjuvant Pembrolizumab for Stage IB-IIIA NSCLC
(Targeted Oncology)
:
Immunotherapy, Targeted Therapy Enter Localized Setting in Non–Small Cell Lung …
(Targeted Oncology)

December 2022

:
FDA Approves Adagrasib for KRAS G12C-Mutant Locally Advanced/Metastatic NSCLC
(Targeted Oncology)

November 2022

:
FDA approves tremelimumab in combination with durvalumab and platinum-based che…
(US Food and Drug Administration)
:
FDA approves cemiplimab-rwlc in combination with platinum-based chemotherapy fo…
(US Food and Drug Administration)

September 2022

:
Sintilimab Plus Chemotherapy Elicits PFS Benefit in EGFR-mutated Non-Squamous N…
(Targeted Oncology)
:
Approaching Treatment for a Patient With NSCLC and an EGFR Mutation
(Targeted Oncology)
:
KEYNOTE-091 Evaluates Adjuvant Pembrolizumab in Resected Early-Stage NSCLC
(Targeted Oncology)
:
PFS With Sotorasib Superior to Standard of Care in KRAS G12C-Mutant NSCLC
(Targeted Oncology)

August 2022

:
FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for HER2+ Metastatic …
(Targeted Oncology)

June 2022

:
Imfinzi plus chemotherapy significantly improved pathologic complete response i…
(Astra Zeneca)
:
Sugemalimab Demonstrates Clinically Meaningful PFS Boost in Unresectable NSCLC
(Targeted Oncology)
:
Lorlatinib reduces CNS progression in ALK-positive NSCLC
(Medpage Today)
:
Nivolumab/ipilimumab shows persistent 5+ year survival benefit in mNSCLC
(Targeted Oncology)

April 2022

:
FDA grants fast track designation to ONC-392 for mNSCLC
(Targeted Oncology)